Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:57:48 EDT Fri 19 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Z:PFE
- PFIZER INC -
http://www.pfizer.com
10:57:48 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
PFE
- Z
1.2
25.58
·
25.59
2.3
25.585
+0.195
0.8
9,345.6
235,933
25,040
25.42
25.62
25.35
40.56 25.26
10:38:03
Apr 11
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
Company
·
Participants
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 25040
More trades...
Time ET
Ex
Price
Change
Volume
10:38:12
Z
25.59
0.20
1
10:38:12
Z
25.58
0.19
223
10:38:11
Z
25.58
0.19
200
10:38:11
Z
25.58
0.19
200
10:38:11
Z
25.58
0.19
100
10:38:11
Z
25.58
0.19
10
10:38:11
Z
25.58
0.19
8
10:38:11
Z
25.59
0.20
150
10:38:11
Z
25.58
0.19
50
10:38:11
Z
25.58
0.19
50
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-04-11 10:00
U:PFE
News Release
200
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
2024-04-09 06:45
U:PFE
News Release
200
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO(TM) in Adults Aged 18 to 59 at Increased Risk for RSV Disease
2024-04-08 12:44
U:PFE
News Release
200
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
2024-03-20 10:00
U:PFE
News Release
200
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
2024-03-13 04:00
U:PFE
News Release
200
European Commission Approves Pfizer's PREVENAR 20(TM) to Help Protect Infants and Children Against Pneumococcal Disease
2024-03-12 06:45
U:PFE
News Release
200
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS(TM) Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2024-03-05 10:00
U:PFE
News Release
200
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-29 17:40
U:PFE
News Release
200
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
2024-02-29 08:00
U:PFE
News Release
200
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO(TM) for RSV in Older Adults
2024-02-26 10:00
U:PFE
News Release
200
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-19 07:45
U:PFE
News Release
200
European Commission Approves Pfizer ¢ € ™s VELSIPITY ‚ ® for Patients with Moderately to Severely Active Ulcerative Colitis
2024-02-15 10:00
U:PFE
News Release
200
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
2024-02-15 08:45
U:PFE
News Release
200
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
2024-02-14 08:30
U:PFE
News Release
200
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-14 08:00
U:PFE
News Release
200
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
2024-02-06 06:45
U:PFE
News Release
200
Arvinas and Pfizer ¢ € ™s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
2024-02-05 10:00
U:PFE
News Release
200
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
2024-02-02 06:45
U:PFE
News Release
200
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2024-01-30 06:45
U:PFE
News Release
200
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
2024-01-26 12:00
U:PFE
News Release
200
European Medicines Agency Validates Type II Variation Application for PADCEV ‚ ® (enfortumab vedotin) with KEYTRUDA ‚ ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer